Seeing is Believing: Wall Street's Slow Reaction to Rimonabant

An FDA advisory committee's recommendation against the approval of Sanofi-Aventis' rimonabant caught many investors off guard. It's hard to believe drug safety issues can still surprise Wall Street, but there are some reasons why analysts lacked clarity on rimonabant.

Sometimes you have to see it to believe it.

Despite all the signs pointing to a fiery demise for Sanofi-Aventis’ rimonabant (Zimulti), Wall Street still appeared caught off guard...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet